González Idilio, Pérez Bárbaro, Alvarez Mayra, Dorado Pedro, Llerena Adrián
Hospital Psiquiátrico de La Habana, La Habana, Cuba, and Facultad de Medicina, Universidad de Extremadura, Centro de Investigación Clínica CICAB.
Med Clin (Barc). 2007 May 26;128(20):772-4. doi: 10.1157/13106328.
CYP2D6 metabolic capacity shows genetic polymorphism. Two metabolic phenotypes, poor and extensive, can be determined by the ratio of debrisoquine to its metabolite in urine (MR). A subgroup of ultrarapids has been also described. We analyzed the inter-ethnic differences on the polymorphic hydroxylation of debrisoquine in a Cuban population in comparison to Spaniards.
MR in a Cuban population of 260 white and mestizo healthy volunteers was studied and compared to 925 Spanish healthy volunteers.
The frequency of poor metabolizer in Cubans (4.6%) was almost identical to that found in Spaniards (4.9%). However, ultrarapids were lower in Cubans (3.8%) than in Spaniards (5.2%). MR in Cuban-mestizo extensive metabolizers was higher than in white (p<0.05).
Interethnic differences on debrisoquine hydroxylation have been demonstrated in a Cuban population. Furthermore, differences on the frequency of ultrarapids between Cubans and Spaniards have been shown. These results could explain inter-individual and interethnic differences on drug response such as side effects or therapeutic failures among Cuban patients receiving treatment with CYP2D6 substrates.
CYP2D6代谢能力存在基因多态性。可通过尿中异喹胍与其代谢物的比值（MR）来确定两种代谢表型，即慢代谢型和快代谢型。此外，还描述了一个超快代谢亚组。我们分析了古巴人群与西班牙人群在异喹胍多态性羟基化方面的种族差异。
对260名古巴白种和混血健康志愿者的MR进行了研究，并与925名西班牙健康志愿者进行了比较。
古巴人群中慢代谢者的频率（4.6%）与西班牙人群中慢代谢者的频率（4.9%）几乎相同。然而，古巴人群中超快代谢者的比例（3.8%）低于西班牙人群（5.2%）。古巴混血快代谢者的MR高于白种人（p<0.05）。
在古巴人群中已证实异喹胍羟基化存在种族差异。此外，还显示了古巴人和西班牙人在超快代谢者频率上的差异。这些结果可以解释在接受CYP2D6底物治疗的古巴患者中，个体间和种族间在药物反应（如副作用或治疗失败）方面的差异。
